iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Show more

Location: 11750 Sorrento Valley Road, San Diego, CA, 92121, United States | Website: https://ibioinc.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

12.38M

52 Wk Range

$0.64 - $6.89

Previous Close

$0.76

Open

$0.75

Volume

781,518

Day Range

$0.72 - $0.76

Enterprise Value

11.97M

Cash

4.959M

Avg Qtr Burn

-3.886M

Insider Ownership

4.31%

Institutional Own.

15.78%

Qtr Updated

03/31/25